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CHOLINESTERASE INHIBITOR: PHARMACOLOGICAL 
APPLICATION 
Alzheimer‘s disease (AD) is a progressive neuro-degenerative disorder which 
was first described by German psychiatrist and neuropathologist Alois Alzheimer in 
1906. AD is the fourth leading cause of death in people over 65 years old 
worldwide [1]. AD is the leading cause of dementia amongst the aging population. 
Although many factors have been involved in AD, its etiology is not completely 
clear. This devastating disorder is generally connected with the gradual memory loss, 
specified by a reduction of acetylcholine level in the cortex hippocampus of the brain 
due to hyperactivation of cholinesterases (acetylcholinesterase (AChE) and 
butyrylcholinesterase (BChE)) [2]. Trial data suggest a reduced emergence of 
behavioral and psychiatric symptoms among patients treated with cholinesterase 
inhibitors. 
AChE and BChE are a part of the serine hydrolase family. They destroy 
choline-based structures and participate in neurotransmission like AChE degradation 
by AChE/BChE or in detoxification of xenobiotics like cocaine, salicylic acid, and 
others by BChE. Violation in AChE neurotransmission - main factor to the 
manifestation of symptoms related to diseases like myasthenia gravis, Parkinson‘s 
disease, AD, glaucoma, etc.  
Tacrine, the first dual inhibitor of both cholinesterases approved by Food and 
Drug Administration (FDA) in 1993, was withdrawn from the pharmaceutical 
market due to its poor oral bioavailability, the necessity of multiple day-doses, and 
a number of serious side effects. Tacrine was prohibited due to its poor oral 
bioavailability, the need of plural day-doses, and some of serious side effects such 
as hepatotoxicity, vomiting, diarrheal disease, urinary incontinence, and potential 
carcinogenicity [2]. 
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Today, THA assist as a useful foundation for the structure of novel agents 
potentially useful for AD treatment. One such substance, namely 7-methoxytacrine 
(7-MEOTA), exhibits an intriguing profile, retaining AChE inhibition properties and 
concomitantly having suppressed hepatotoxicity [2]. The results of some 
development of previous studies have shown that both tacrine and 7-MEOTA are 
capable of binding to the peripheral anionic site (PAS), as well as to the AChE 
catalytic anionic site (CAS), depending on the structure of the second attached 
fragment. Significant role plays a length of the alkyl chain in ensuring of proper 
contact with both crucial sections of the enzyme. 
Different important class of AChE inhibitors presents Huprines, designed by 
merging two fragments of the known AChE inhibitors-THA and huperzine A. Some 
parts of this compound family are more potent human AChE inhibitors than the 
parent compounds. The most promising are so-called huprines X and Y [3].   
Today approved drugs for the treatment of mild or moderate AD stages are 
donepezil, rivastigmine, and galantamine. They provide symptomatic treatment by 
improving cholinergic neurotransmission via inhibition of AChE to improve the 
quality of life of AD patients. Though they share the same mechanism of effect, they 
differ in terms of their route of administration and pharmacologic effects, which can 
impact their safety and bioavailability. Rivastigmine, available in both oral and 
transdermal patch formulations, is a slowly reversible dual inhibitor of acetyl and 
butyryl cholinesterase, selective for the G1 isoform of acetylcholinesterase. Despite 
its unique features, it was associated with a higher incidence of side effects compared 
to other drugs [2]. 
A research has demonstrated clinical benefits of sustained cholinesterase 
inhibition with rivastigmine in AD and Parkinson's disease dementia (PDD). 
Rivastigmine is a unique cholinesterase inhibitor with both AChE and BuChE 
inhibitory activity, unlike donepezil and galantamine that selectively inhibit AChE. 
Scientists suggest that the dual inhibition of AChE and BuChE may afford additional 
medication potential of rivastigmine in subcortical dementias (subcortical PDD) with 
benefits on cognition and behavioral symptoms [4].   
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Furthermore, evidence shows that acetylcholine plays a role in suppression of 
cytokine release through a "cholinergic anti-inflammatory pathway" which raises 
questions about the role of these inhibitors in the immune system. Several review 
covers research and discussion of the role of the inhibitors in modulating the immune 
response using as examples the commonly available medicine, donepezil, 
galantamine, huperzine, neostigmine and pyridostigmine. Great attention is given to 
the cholinergic anti-inflammatory pathway, a well-described link between the central 
nervous system and terminal effector cells in the immune system. 
Due to the complex pathogenesis of AD, currently, there is no ideal drug for the 
prevention or treatment of AD. Thus, the treatment of AD remains a challenge in the 
pharmaceutical community. And today AChE inhibitors like tacrine and donepezil 
the only drugs against of AD. 
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